




Healthcare Industry News: Betaseron
News Release - October 12, 2006
KaloBios Pharmaceuticals Appoints David W. Pritchard as President and Chief Executive Officer
PALO ALTO, Calif.--(HSMN NewsFeed)--KaloBios Pharmaceuticals Inc., a privately held biopharmaceutical company, today announced the appointment of David W. Pritchard as president and chief executive officer."David's extensive experience in corporate financing and negotiation of major corporate partnerships will enable KaloBios to realize the value of its antibody technology platform and product portfolio," said James Healy, chairman of the Board of KaloBios.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals is a therapeutic antibody company using its proprietary antibody engineering, humaneering(TM) and expression technologies for the development of a pipeline of antibody therapeutics. Its two most advanced drug candidates are KB001 and KB002. KB001 is designed to treat life-threatening Pseudomonas lung infections, a common problem of cystic fibrosis and mechanically ventilated patients. KB002 is designed for the treatment of Rheumatoid arthritis and other autoimmune diseases. For more information, visit www.kalobios.com.
Source: KaloBios Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.